QSAM Biosciencesの収入

QSAM Biosciencesの収入 は何ですか。

QSAM Biosciences, Inc.の収入 は-8.73$です。

収入 の定義は何ですか。

普通株主に帰属する当期純利益は、純利益から優先配当金を差し引いた金額です。優先配当

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

OTCのセクタHealth Careにおける収入 の企業と比べるQSAM Biosciences

QSAM Biosciencesは何をしますか。

QSAM Biosciences, Inc., a clinical stage biotechnology company, develops drugs for the treatment of bone cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage novel radiopharmaceutical for the treatment of bone cancer and related diseases. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was founded in 2004 and is based in Austin, Texas.

QSAM Biosciencesと類似の収入